Skip to main content
NFL Biosciences logo

NFL Biosciences — Investor Relations & Filings

Ticker · ALNFL ISIN · FR0014003XT0 LEI · 9695006VJWNTN4UNHA27 PA Professional, scientific and technical activities
Open in API
Filings indexed 187 across all filing types
Latest filing 2026-06-01 Regulatory Filings
Country FR France
Listing PA ALNFL

About NFL Biosciences

https://www.nflbiosciences.com/

NFL Biosciences is a biopharmaceutical company that develops botanical drug candidates for the treatment of addictions. The company's lead product, NFL-101, is a nicotine-free drug candidate for smoking cessation derived from a protein extract of tobacco leaves. Its development pipeline also includes NFL-301, a candidate aimed at reducing excessive alcohol consumption. NFL Biosciences focuses on advancing its products through clinical trials with the goal of licensing them to pharmaceutical companies for commercialization.

Recent filings

Filing Released Lang Actions
Modalités de mise à disposition des documents préparatoires à l'AG
Regulatory Filings Classification · 75% confidence The document is a press release notifying shareholders of the upcoming mixed Annual General Meeting (June 17, 2026), the prior publication of the meeting notice in the BALO, and the availability of preparatory documents on the company website. It does not itself contain AGM materials or financial statements, nor is it a proxy solicitation or full annual/interim report. This is a general regulatory announcement about document availability and meeting logistics, best fitting the Regulatory Filings (RNS) category.
2026-06-01 French
Inside Information / Other news releases
Regulatory Filings Classification · 82% confidence The document is a corporate press release detailing clinical trial results for NFL-101, including biomarker analyses, efficacy tables, and future development plans. It contains no financial statements, share transactions, meeting materials, or proxy-related content, nor is it a regulatory report or investor presentation. It serves as a general corporate announcement, fitting the fallback category for miscellaneous regulatory and press disclosures.
2026-06-01 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a corporate press release (communiqué de presse) announcing new clinical trial results and strategic development plans for NFL-101. It contains detailed scientific data and market perspectives but no financial statements, earnings figures, regulatory filings, or investor presentation materials. It does not fit any specialized financial filing category (e.g., Annual Report, Earnings Release, Interim Report, Investor Presentation, etc.) and is a general corporate announcement. Therefore, it falls under the fallback category for miscellaneous regulatory/press announcements: Regulatory Filings (RNS).
2026-06-01 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 55% confidence The document is a press release (communiqué de presse) announcing the filing of a new patent application and related R&D developments at NFL Biosciences. It contains no financial statements, no meeting results, no director changes, and no regulatory form citations. It is not an earnings release, not a report publication announcement, nor a board/management update, but rather a general corporate announcement. Therefore it falls into the miscellaneous regulatory announcements category.
2026-05-25 French
Inside Information / Other news releases
Regulatory Filings Classification · 80% confidence The document is a corporate press release announcing the filing of a new patent application for a biomarker related to the company’s drug candidate. It does not contain financial results, regulatory certifications, meeting materials, or any specialized report (e.g., annual report, interim report, proxy statement, share issuance). It is not an AGM or earnings release, nor is it any governance, financing, or legal filing. As a general corporate announcement outside the other specific categories, it falls into the fallback category of “Regulatory Filings (RNS).”
2026-05-25 English
Inside Information / Other news releases
Regulatory Filings Classification · 93% confidence The text is a corporate press release from NFL Biosciences detailing R&D objectives and biomarker evaluation criteria. It is not a financial report, earnings release, management presentation, or formal regulatory form. It is a general announcement to investors and the market, fitting the fallback category for miscellaneous regulatory announcements. Therefore, it should be classified as a Regulatory Filing (RNS).
2026-05-11 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.